Bristol-Myers Squibb (NYSE:BMY) Stock Holdings Lessened by Arlington Partners LLC

Arlington Partners LLC lowered its stake in shares of Bristol-Myers Squibb (NYSE:BMY) by 11.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 80,797 shares of the biopharmaceutical company’s stock after selling 10,000 shares during the quarter. Bristol-Myers Squibb comprises about 1.8% of Arlington Partners LLC’s holdings, making the stock its 5th largest position. Arlington Partners LLC’s holdings in Bristol-Myers Squibb were worth $4,570,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Soltis Investment Advisors LLC lifted its position in Bristol-Myers Squibb by 6.2% in the fourth quarter. Soltis Investment Advisors LLC now owns 7,843 shares of the biopharmaceutical company’s stock valued at $444,000 after purchasing an additional 461 shares during the period. Quilter Plc lifted its position in Bristol-Myers Squibb by 56.6% in the fourth quarter. Quilter Plc now owns 107,818 shares of the biopharmaceutical company’s stock valued at $6,098,000 after purchasing an additional 38,977 shares during the period. Silicon Valley Capital Partners acquired a new stake in Bristol-Myers Squibb in the fourth quarter valued at about $40,000. Wingate Wealth Advisors Inc. acquired a new stake in Bristol-Myers Squibb in the fourth quarter valued at about $146,000. Finally, Four Tree Island Advisory LLC acquired a new stake in Bristol-Myers Squibb in the fourth quarter valued at about $2,928,000. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Bristol-Myers Squibb Stock Down 0.8 %

BMY stock opened at $56.96 on Monday. The stock has a market capitalization of $115.51 billion, a P/E ratio of -12.89, a PEG ratio of 2.13 and a beta of 0.45. The company has a debt-to-equity ratio of 2.83, a quick ratio of 1.09 and a current ratio of 1.24. Bristol-Myers Squibb has a one year low of $39.35 and a one year high of $61.10. The company has a 50 day moving average price of $57.56 and a two-hundred day moving average price of $53.83.

Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, February 6th. The biopharmaceutical company reported $1.67 EPS for the quarter, topping the consensus estimate of $1.47 by $0.20. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.81%. As a group, sell-side analysts expect that Bristol-Myers Squibb will post 6.75 EPS for the current year.

Bristol-Myers Squibb Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, February 3rd. Stockholders of record on Friday, January 3rd were paid a dividend of $0.62 per share. The ex-dividend date was Friday, January 3rd. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.60. This represents a $2.48 annualized dividend and a dividend yield of 4.35%. Bristol-Myers Squibb’s payout ratio is currently -56.11%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. Wolfe Research assumed coverage on shares of Bristol-Myers Squibb in a research report on Friday, November 15th. They set a “peer perform” rating for the company. Leerink Partners upgraded shares of Bristol-Myers Squibb from a “market perform” rating to an “outperform” rating and lifted their price target for the company from $55.00 to $73.00 in a research report on Tuesday, November 12th. Bank of America reiterated a “neutral” rating and set a $63.00 price target on shares of Bristol-Myers Squibb in a research report on Tuesday, December 10th. Truist Financial lifted their price target on shares of Bristol-Myers Squibb from $62.00 to $65.00 and gave the company a “buy” rating in a research report on Wednesday, January 8th. Finally, Citigroup lifted their price target on shares of Bristol-Myers Squibb from $60.00 to $65.00 and gave the company a “neutral” rating in a research report on Tuesday, January 28th. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, four have assigned a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat.com, Bristol-Myers Squibb has an average rating of “Hold” and an average target price of $57.86.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.